Bioinvent International AB is banking an up-front payment of $25 million as part of an option and license agreement with Exelixis Inc., which aims to discover antibodies acting on new immuno-oncology targets. Further financial details were not disclosed, but the alliance entails the discovery of three novel targets and their associated antibodies, identified through Bioinvent’s F.I.R.S.T. screening platform and its n-Coder antibody library.
Imcheck Therapeutics SAS raised €80 million (US $83.5 million) in a series C round to maintain the momentum of its lead development program, ICT-01, an immunostimulatory antibody that activates gamma-delta T cells.
Immunos Therapeutics AG closed a $74 million series B round to progress its first-in-class, multifunctional immuno-oncology drug candidate, IOS-1002, and to expand further its pipeline of biologic drugs based on immuno-stimulatory human leukocyte antigen molecules.
Shares in Swedish biotech firm Rhovac AB collapsed May 30 on news that its therapeutic cancer vaccine, RV-001 (onilcamotide), failed to exhibit efficacy in a phase IIb trial in metastatic prostate cancer. The stock lost 94% of its value when trading opened on the Spotlight junior exchange in Stockholm.
Microbiome-modulating therapies are increasingly being explored to treat a variety of diseases. However, the market is still in its infancy and a lack of solid regulations remains challenging for companies to overcome, speakers at the BioKorea 2022 said May 11.
Microbiome-modulating therapies are increasingly being explored to treat a variety of diseases. However, the market is still in its infancy and a lack of solid regulations remains challenging for companies to overcome, speakers at the BioKorea 2022 said May 11.
Beigene Ltd. reported that its global phase III trial of PD-1 inhibitor tislelizumab in combination with chemotherapy met the primary endpoint of overall survival in first-line advanced esophageal cancer.
Beigene Ltd. reported that its global phase III trial of PD-1 inhibitor tislelizumab in combination with chemotherapy met the primary endpoint of overall survival in first-line advanced esophageal cancer.
Epitopea Ltd. raised $13.6 million in seed financing to take forward a new cancer immunotherapy platform based on the identification of a new class of tumor-specific antigens encoded by non-canonical genomic sequences.
Odeon Therapeutics Inc. has acquired rights to two cancer candidates from Obi Pharma Inc. in a deal worth up to $200 million. The transaction gives Shanghai-based Odeon rights to develop, register, and commercialize the antibody-drug conjugate OBI-999 and a therapeutic cancer vaccine OBI-833 in mainland China, Hong Kong, and Macau.
